Scientific Conference Agenda

Malignant Hyperthermia (MH)- New Insights and Connections with other Myopathies

Conference Objectives

To discuss new advances in the pathophysiology of MH and to gain insight into the role of the skeletal muscle ryanodine receptor, type 1 (RYR1) and other genes in MH and other related disorders.

To promote understanding of how MH susceptibility relates to other muscle disorders (e.g. Central Core Disease (CCD), muscular dystrophies, metabolic myopathies).

To discuss advances in the genetics of MH and improvements in diagnosis for MH susceptibility.

To improve the ability of anesthesiologists who volunteer as consultants (the HLCs) to provide up-to-date support to medical practitioners on the identification and management of MH and other muscle disorders.

To introduce young anesthesiologists and other interested investigators to this area of medicine.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of SUNY Upstate Medical University and the Malignant Hyperthermia Association of the United States (MHAUS). SUNY Upstate Medical University is accredited by the ACCME to provide continuing medical education for physicians.

SUNY Upstate Medical University designates this educational activity for a maximum of 13.75 AMA PRA Category 1 Credit(s) (TM). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Please note:
Funding for this conference was made possible (in part) by an R13 Grant (1 R13AR05422-01) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), including co-funding from the Office of Rare Disease Research (ORDR). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

AGENDA Day 1- Friday, April 23, 2010

POSTERS SHOULD BE SET UP 7:00-8:00 AM

Time	Topic	Speaker(s)
8:00-8:30	Welcome and Introductions	Henry Rosenberg, MD, President, MHAUS Andrew Herlich, MD, UPMC and John P. Williams, M.D., UPMC
Session 1	Pathophysiology of MH – Overview and Recent Advances in Understanding	Session Chairperson: Jerome Parness, MD, PhD, UPMC
8:30-9:00	Introduction to MH Pathophysiology; fresh approaches to understanding MH at cellular level; dantrolene & mechanism of action	Jerome Parness, MD, PhD, UPMC
9:00-9:45	Lessons from a Mouse Model of Malignant Hyperthermia: Mechanisms and New Interventions 9:45-10:00: Questions/Discussion	Susan Hamilton, PhD, Baylor College of Medicine Keynote Speaker
10:00-10:30	Mechanistic Models for the Cause of MH and for Core Formation in CCD 10:30-10:45 Questions/Discussion	David MacLennan, PhD University of Toronto
10:45-11:15	COFFEE BREAK
11:15-11:45	New Frontiers in Personalized Medicine: RyR1 Allele-Specific Gene Silencing in Mouse Models of MH and CCD 11:45-12:00: Questions/Discussion	Robert T. Dirksen, PhD University of Rochester
12:00-12:30	Changes in DHPR kinetics induced by MH related conformational changes in RyR1 12:30-12:45: Questions/Discussion	Paul Allen, MD, PhD Brigham and Women’s
12:45-1:45	LUNCH
Session 2	Genetics of MH: Results and Future Directions	Chairperson: Sheila Muldoon, MD, USUHS
1:45-2:15	Genetics testing for MH susceptibility in Europe; role of new diagnostic testing strategies in evaluating MH risk	Henrick Rueffert, MD University of Leipzig, Germany
2:15-2:45	Reassessment of the operating characteristics of IVCT given genetic RYR1 results; update on the EMHG Reference: Improve on Phenotyping	Thierry Girard, MD University Hospital of Basel, Switzerland
2:45-3:15	Results of genetic testing (RYR1 gene findings) in basic research laboratories	Khishge Sambuughin, PhD, USUHS
3:15-3:30	COFFEE BREAK
3:30-4:00	Assessment of RYR1 gene variants for Pathogenicity: Theory and Examples	Jeffrey Kant, MD, PhD UPMC
4:00-4:30	Results of genetic testing (RYR1 gene findings) in CLIA-approved clinical laboratories	Jim Weber, PhD Prevention Genetics
4:30-5:15	Discussion of related questions	Sheila Muldoon, MD USUHS
5:15-6:30	POSTER SESSION One, Two, Three, Four, Five, Six, Seven, Eight, Nine, Ten

AGENDA Day 2- Saturday, April 24, 2010

Time	Topic	Speaker(s)
8:00-8:30	Welcome, Comment on Day 1	Sheila Muldoon, MD, USUHS
Session 3	Relationship between MH-susceptibility and other muscle conditions/disorders	Chairperson: Barbara Brandom, MD, UPMC
8:30-8:45	Review of 2008 SPA Meeting Recommendations (anesthetic considerations in MH-associated diseases)	Barbara Brandom, MD UPMC
8:45-9:15	Creatine Kinase and Heat Tolerance in Mice and Men 9:15-9:30: Questions/Discussion	Patricia Deuster, PhD, MPH USUHS
9:30-10:00	COFFEE BREAK
10:00-10:30	Confounding Cases: Is this MH and How Would You Provide Anesthesia? 10:30-10:45: Questions/Discussion	John Capacchione, MD USUHS
10:45-11:15	Genetic susceptibility to statin-induced myopathy 11:15-11:30: Questions/Discussion	Georgirene Vladutiu, PhD SUNY at Buffalo
11:30-1:00	LUNCH & ADDITIONAL TIME TO VISIT POSTERS
Session 4	MH Epidemiology	Chairperson: Henry Rosenberg, President, MHAUS
1:00-1:15	Introduction to Epidemiology of MH; role of MH Hotline and North American MH Registry (NAMHR) databases as research and educational tools; implications and limitations of epidemiologic studies, Epidemiology Slide Handout	Henry Rosenberg President, MHAUS
1:15-1:45	MH Comorbidities 1:45-2:00: Questions/Discussion	Joanne E. Brady, SM, Columbia University
2:00-2:45	What the Registry has Taught Us: MH Presentation, Treatment, and Outcome; Is it Time for Revisions to MHAUS Clinical Care Recommendations? Reference: Cardiac Arrests, Reference: Clinical Presentation 2:45-3:00: Questions/Discussion	Marilyn Larach, MD Penn State College of Medicine
3:00-3:15	COFFEE BREAK
Session 5	Future Directions/Challenges	Chairperson: Henry Rosenberg, MD, President, MHAUS
3:15-3:30	Changing Recommendations for Anesthesia Machine Preparation 3:30-3:45: Questions/Discussion	David Rymer, MD UPMC
3:45-4:00	Need for building the NAMHR database as source for future clinical trials; Recent reporting trends; Current contributions from the MH Diagnostic Centers	Barbara Brandom, MD UPMC
4:00-4:30	Patient Safety First	Dale Micalizzi Board of Directors, MHAUS
4:30-5:00	Closing Remarks: Future directions for MH – research and non-invasive diagnostic testing; Future Directions for MHAUS –patient safety initiatives (ambulatory surgery issues, educational initiatives [simulation]); advice for MHS individuals.	Henry Rosenberg, MD MHAUS